Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 235-238

  Mattsson, J ^a   Nordlander, A ^a   Remberger, M ^a   Uhlin, M ^a   Holgersson, J ^a   Ringden O ^a   Hauzenberger, D ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic; Crossmatch; Graft failure; Rejection; SCT

Indexed keywords

BUSULFAN; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; B LYMPHOCYTE; BLOOD GROUP TYPING; BONE MARROW CELL; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY TEST; DIAGNOSTIC VALUE; DONOR; DONOR SELECTION; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PERIPHERAL BLOOD STEM CELL; PREDICTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 76749162264     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.144     Document Type: Article

References (25)

1. Sumitran-Karuppan S, Tyden G, Reinholt F, Berg U, Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5: 321-327.
2. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17: 541-545.
3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
4. Ting A, Hasegawa T, Ferrone S, Reisfeld RA. Presensitization detected by sensitive crossmatch tests. Transplant Proc 1973; 5: 813-817.
5. Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 2006; 1: 404-414.
6. Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb HJ, Lerner KG et al. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1974; 112: 1508-1516.
7. Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109: 1307-1315.
8. Xu H, Chilton PM, Tanner MK, Huang Y, Schanie CL, Dy-Liacco M et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611-3619.
9. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
10. Ottinger HD, Rebmann V, Pfeiffer KA, Beelen DW, Kremens B, Runde V et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002; 73: 1280-1285.
11. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196-2201.
12. Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006; 82: 913-919.
13. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122-127.
14. Schaffer M, Aldener-Cannava A, Remberger M, Ringden O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 2003; 62: 243-250.
15. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735. (Pubitemid 16124386)
16. Nordlander A, Mattsson J, Sundberg B, Sumitran-Holgersson S. Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation. Transplantation 2008; 86: 686-696.
17. Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002; 100: 4317-4324.
18. Karuppan SS, Lindholm A, Moller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 1992; 53: 666-673.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.
21. Maris M, Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003; 28: 13-24.
22. Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14 (Suppl 1): 165-170.
23. Baron F, Storer B, Maris MB, Storek J, Piette F, Metcalf M et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1176-1187.
24. Akalin E, Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 433-440.
25. Kataoka K, Yamamoto G, Nannya Y, Yoshimi A, Okada S, Asai T et al. Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti- HLA Abs. Bone Marrow Transplant 2008; 42: 129-130.